Monika Lamparska-Przybysz
- Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disordersBy Pawel Gunerka, Barbara Dymek, Daria Zdzalik, Marcin Zagozda, Maciej Dziachan, Maciej Malczyk, Anna Bujak, Paulina Grygielewicz, Olga Musielak, Monika Skupinska, Joanna Hucz-Kalitowska, Krzysztof Dubiel, Monika Lamparska-Przybysz, Maciej Wierczorek and Aleksandra StanczakPawel Gunerka1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, Poland3Department of Medical Biotechnology, Medical University of Lodz, Lodz, PolandBarbara Dymek1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandDaria Zdzalik1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMarcin Zagozda1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMaciej Dziachan1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMaciej Malczyk1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandAnna Bujak1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, Poland2Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, PolandPaulina Grygielewicz1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, Poland2Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, PolandOlga Musielak1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMonika Skupinska1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandJoanna Hucz-Kalitowska1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandKrzysztof Dubiel1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMonika Lamparska-Przybysz1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMaciej Wierczorek1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandAleksandra Stanczak1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, Poland
- Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthmaBy Anna Bujak, Patrycja Nejman-Gryz, Pawel Gunerka, Monika Lamparska-Przybysz, Maciej Wieczorek, Ryszarda Chazan and Aleksandra StanczakAnna Bujak1Innovative Drugs R&D Department, Celon Pharma Inc., Kielpin/Lomianki, Poland2Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, PolandPatrycja Nejman-Gryz3Deptartment of Internal Diseases, Pneumology and Allergology, Medical University of Warsaw, Warsaw, PolandPawel Gunerka1Innovative Drugs R&D Department, Celon Pharma Inc., Kielpin/Lomianki, Poland4Department of Medical Biotechnology, Medical University of Lodz, Lodz, PolandMonika Lamparska-Przybysz1Innovative Drugs R&D Department, Celon Pharma Inc., Kielpin/Lomianki, PolandMaciej Wieczorek1Innovative Drugs R&D Department, Celon Pharma Inc., Kielpin/Lomianki, PolandRyszarda Chazan3Deptartment of Internal Diseases, Pneumology and Allergology, Medical University of Warsaw, Warsaw, PolandAleksandra Stanczak1Innovative Drugs R&D Department, Celon Pharma Inc., Kielpin/Lomianki, Poland
- Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthmaBy Pawel Gunerka, Barbara Dymek, Daria Zdzalik, Michal Mroczkiewicz, Joanna Lipner, Bartosz Stypik, Anna Bujak, Paulina Grygielewicz, Olga Musielak, Monika Skupinska, Joanna Hucz-Kalitowska, Krzysztof Dubiel, Monika Lamparska-Przybysz, Maciej Wieczorek and Aleksandra StanczakPawel Gunerka1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, Poland2Department of Medical Biotechnology, Medical University of Lodz, Lodz, PolandBarbara Dymek1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandDaria Zdzalik1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMichal Mroczkiewicz1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandJoanna Lipner1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandBartosz Stypik1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandAnna Bujak1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, Poland3Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, PolandPaulina Grygielewicz1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, Poland3Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, PolandOlga Musielak1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMonika Skupinska1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandJoanna Hucz-Kalitowska1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandKrzysztof Dubiel1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMonika Lamparska-Przybysz1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandMaciej Wieczorek1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, PolandAleksandra Stanczak1Innovative Drugs R&D Department, Celon Pharma S.A., Lomianki, Poland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
